RECRUITINGPhase 4INTERVENTIONAL
Once Weekly Infant Corticosteroid Trial for DMD
Phase-2 Trial of 5mg/kg/Week Prednisolone in Young Boys With DMD
About This Trial
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
Who May Be Eligible (Plain English)
Who May Qualify:
- Subjects ages 1 month through 30 months
- Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.
Who Should NOT Join This Trial:
- Prior treatment with Glucocorticosteroids
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Subjects ages 1 month through 30 months
* Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.
Exclusion Criteria:
* Prior treatment with Glucocorticosteroids
Treatments Being Tested
DRUG
Prednisolone
Liquid, 5mg/kg per week, for one year
Locations (4)
Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
University of Cincinnati
Cincinnati, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
University of Texas Southwestern
Dallas, Texas, United States